Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux.
Unexpected bleeding disorders: Algorithm for approach to therapy.
Inhibitor antibodies to factor VIII and factor IX: management.
New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate.
Prescribing Info - Questions - Drug Info - Links - PDA Software - Article Summaries - Slideshows - Review Articles - What's New
 
© Copyright 1999-2017 DocMD.com. All Rights Reserved.